| |
Publications
Publications with authors from Hemostasis Reference Laboratory
2005
Vlasin M, Rak J, Weitz JI, Peng L, Gumulec J, Johnston M, Klement P. Heparin Compromises Streptokinase-induced Arterial Patency in Rabbits. Thrombosis Research 2005; 115: 427-434.
2004
van den Besselaar AMHP, Barrowcliffe TW, Houbouyan-Reveillard LL, Jespersen J, Johnston M, Poller L, Tripodi A. Guidelines on Preparation, Certification, and Use of Certified Plasmas for ISI Calibration and INR Determination. Journ of Thromb and Haemost 2004;2:1946-1953.
2003
Bates SM, Kearon K, Crowther M, Linkins L, O'Donnell M, Douketis J, Lee AYY, Weitz JI, Johnston M, Ginsberg JS. A Diagnostic Strategy Involving a Quantitative Latex D-Dimer Assay Reliably Excludes Deep Vein Thrombosis. Ann Intern Med 2003;138:787-794.
Klement P, Carlsson S, Rak J, Liao P, Vlasin M, Stafford A, Johnston M, Weitz JI. The Benefit-to-risk profile of Melagatran is Superior to that of Hirudin in a Rabbit Arterial Thrombosis Prevention and Bleeding Model. Thromb Haemost 2003;1:587-594.
2002
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. Circulation 2002; 105: 1650-1655.
2001
Bates SM, Grand'Maison A, Johnston M, Naguit I, Kovacs MJ, Ginsberg JS. A Latex D-Dimer Reliably Excludes Venous Thromboembolism. Arch Intern Med 2001; 161: 447-453.
Kearon C, Ginsberg JS, Douketis J, Crowther M, Brill-Edwards P, Weitz JI et al. Management of suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and D-Dimer Testing. Ann Intern Med. 2001;135:108-11.
Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a Fixed Activated Partial Thromboplastin Time Ratio to Establish a Therapeutic Range for Unfractionated Heparin. Arch Intern Med 2001;161:385-91.
2000
Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, ThŽroux P, Marquis J -F, Chan YK, Venkatesh G, Jessel A, for the OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Pilot Study Investigators. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. Eur Heart J 2000;21:1473-1481.
Gosselin R, Owings JT, White RH, Hutchison R, Branch J, Mahackian K, Johnston M, Larkin EC. A Comparison of Point-of-Care Instruments Designed for Monitoring Oral Anticoagulation with Standard Laboratory Methods. Thromb Haemost 2000; 83: 698-703.
Douketis JD, Gordon M, Johnston M, Jullian JA, Adachi JR, Ginsberg J. The Effects of Hormone Replacement Therapy on Thrombin Generation, Fibrinolysis Inhibition, and Resistance to Activated Protein C: Prospective Cohort Study and Review of the Literature. Thromb Res 2000; 99: 25-34.
Male C, Johnston M, Sparling C, Brooker L, Andrew M, Massicotte P. The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. Clin Lab Med 1999; 19(1): 39-69.
19991999
Johnston M, Adcock DM. International Normalized Ratio: Problems and solutions. Clinical Hemostasis Review 1999;13(5): 6-7.
Lee AY, Julian JA, Levine MN, Weitz JI, Kearon C, Wells PS, et al. Clinical Utility of a Rapid Whole-blood D-Dimer Assay in Patients with Cancer Who Present with Suspected Acute Deep Venous Thrombosis. Ann Intern Med. 1999;131:417-23.
van den Besselaar AM, Houbouyan LL, Aillaud MF, Denson KW, Johnston M, Kitchen S, Lindahl TL, Marren M, Martinuzzo ME, Droulle C, Tripodi A, Vergnes C. Influence of three types of automated coagulometers on the international sensitivity index (ISI) of rabbit, human, and recombinant human tissue factor preparations - a multicenter study. Thromb Haemost 1999;81(1): 66-70.
Weitz JI, Young E, Johnston M, Stafford AR, Fredenburgh JC, Hirsh J. Vasoflux, a new anticoagulant with a novel mechanism of action. Circ 1999;99: 682-689.
1998
Brigden ML, Johnston M, for the Thrombosis Interest Group of Canada. INR reporting in Canadian medical laboratories. An update. Am J Clin Pathol 1998; 109: 589-594.
Monagle P, Andrew M, Halton J, Marlar R, Jardine L, Vegh P, Johnston M, Webber C, Massicotte MP. Homozygous protein C deficiency: Description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost 79: 756-761, 1998
Johnston M, Brigden M, for the Thrombosis Group of Canada. A cross-Canada survey of prothrombin time testing. Does the establishment of local ISI values improve the accuracy of international normalized ratio reporting? Am J Clin Pathol 1998; 110: 683-690.
Klement P, Liao P, Hirsh J, Johnston M, Weitz JI. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. J Lab Clin Med 1998;132: 181-186.
Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998; 158(10): 1140-1143.
|
|
 |
NOW AVAILABLE!!
Microparticle Activity Analysis
For more information see our News and Upcoming Events page.
Genotyping for Warfarin Therapy Cytochrome
P450 2C9 gene (CYP2C9) & Vitamin K Epoxide Reductase Complex 1 gene (VKORC1) genotyping is now available. For more information see our News and Upcoming Events page.
XXII Congress of the International
Society on Thrombosis and
Haemostasis
The XXII ISTH Congress is to be held in Boston from July 11 to 16, 2009. Marilyn Johnston has had two abstracts accepted for poster presentation and publication. For more information see our News and Upcoming Events page.
Molecular Cancer Therapeutics
Article
HRL is pleased to inform of a publication by
Lucy Shin, the recipient of the HRL Scholarship for 2006, titled "Effects of the chemotherapeutic agent doxorubicon on the protein C anticoagulant pathway". For more information see our News and Upcoming Events page.
PROCALCITONIN
Testing
The B·R·A·H·M·S PCT LIA assay has been cleared by the FDA for the early diagnosis of patients at risk for progression to severe sepsis.
HRL offers Procalcitonin (PCT) testing for research purposes. The clinical utility in select patient populations has already been identified and continued studies to discover the optimal utilization of this marker as it relates to patient management is foreseen. The availability of this FDA-cleared PCT
assay will encourage further international
clinical-scientific studies. Click here to view the News and Upcoming Events page. |
|
|
